Free Trial

Qiagen (QGEN) Stock Forecast & Price Target

Qiagen logo
$42.78 +0.45 (+1.06%)
(As of 11/22/2024 ET)

Qiagen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
6

Based on 10 Wall Street analysts who have issued ratings for Qiagen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 4 have given a hold rating, and 6 have given a buy rating for QGEN.

Consensus Price Target

$50.88
18.93% Upside
According to the 10 analysts' twelve-month price targets for Qiagen, the average price target is $50.88. The highest price target for QGEN is $60.00, while the lowest price target for QGEN is $45.00. The average price target represents a forecasted upside of 18.93% from the current price of $42.78.
Get the Latest News and Ratings for QGEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Qiagen and its competitors.

Sign Up

QGEN Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$50.88$50.12$51.10$53.40
Forecasted Upside18.93% Upside20.63% Upside11.03% Upside26.68% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

QGEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

QGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Qiagen Stock vs. The Competition

TypeQiagenMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside18.93% Upside27,006.27% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent QGEN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/17/2024Hsbc Global Res
0 of 5 stars
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
10/17/2024HSBC
2 of 5 stars
 DowngradeBuy ➝ Hold$49.00+13.40%
8/2/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$49.00 ➝ $52.00+12.68%
6/27/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Schenkel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$50.00+22.76%
6/18/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$52.00 ➝ $54.00+22.42%
5/1/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$55.00 ➝ $45.00+6.31%
2/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$49.48 ➝ $51.00+19.38%
2/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$61.86 ➝ $60.00+36.36%
12/19/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$45.36+3.87%
12/7/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$51.55+20.61%
11/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$49.48 ➝ $43.30+9.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:24 AM ET.


QGEN Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Qiagen is $50.88, with a high forecast of $60.00 and a low forecast of $45.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.

According to analysts, Qiagen's stock has a predicted upside of 18.93% based on their 12-month stock forecasts.

Over the previous 90 days, Qiagen's stock had 1 upgrade and 1 downgrade by analysts.

Qiagen has been rated by research analysts at Hsbc Global Res, and HSBC in the past 90 days.

Analysts like Qiagen less than other "medical" companies. The consensus rating score for Qiagen is 2.60 while the average consensus rating score for "medical" companies is 2.80. Learn more on how QGEN compares to other companies.


This page (NYSE:QGEN) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners